双唾液酸神经节苷脂及其相关抗体与儿童实体肿瘤的生物学进展和临床研究现状  

Biological progress and clinical research status of disialoganglioside and its related antibodies with pediatric solid tumors

作　　者：蒋持怡 苏雁[1] Jiang Chiyi;Su Yan(Medical Oncology Department/Laboratory for Clinical Medicine,Capital Medical University/Key Laboratory of Major Diseases in Children,Ministry of Education/Beijing Children′s Hospital,Capital Medical University,National Center for Children′s Health,Beijing 100045,China)

机构地区：[1]国家儿童医学中心,首都医科大学附属北京儿童医院肿瘤内科,儿童肿瘤发病机制与创新药物研究联合实验室,儿科重大疾病研究教育部重点实验室,北京100045

出　　处：《中华实用儿科临床杂志》2024年第9期701-706,共6页Chinese Journal of Applied Clinical Pediatrics

基　　金：北京市自然科学基金(7222054);北京市研究型病房建设项目(BCRW202101)。

摘　　要：目前儿童实体瘤的治疗模式包括化疗、手术、移植和放疗等。尽管多学科治疗积极发展,但高危转移性和/或复发性恶性肿瘤患儿的长期预后仍面临艰巨挑战。双唾液酸神经节苷脂(GD2)是一种肿瘤相关抗原,是癌症免疫治疗的主要理想靶点之一。近年来,抗GD2单克隆抗体的免疫治疗方案逐渐应用于高危神经母细胞瘤、骨肉瘤、软组织肉瘤等儿童肿瘤的临床诊疗。现就GD2与儿童实体瘤的生物学关系及抗GD2免疫疗法的临床研究现状进行综述,为国内开展该疗法诊治各类儿童恶性实体瘤提供理论和实践依据。Current treatment modalities for pediatric solid tumors include chemotherapy,surgery,transplantation,radiotherapy,etc.Despite the positive development of multidisciplinary treatment,the long-term prognosis of children with high-risk metastatic and/or recurrent malignant tumors remains challenging.Disialoganglioside(GD2),a tumor-associated antigen,is one of the main ideal targets for cancer immunotherapy.In recent years,immunotherapy with anti-GD2 monoclonal antibodies has been gradually applied in the clinical diagnosis and treatment of high-risk neuroblastoma,osteosarcoma,soft tissue sarcoma and other pediatric tumors.This article reviews the biological relationship between GD2 and pediatric solid tumors and the clinical research status of anti-GD2 immunotherapy,to provide theoretical and practical evidence for the diagnosis and treatment of various pediatric malignant solid tumors in China.

关 键 词：儿童 实体瘤 双唾液酸神经节苷脂 免疫治疗 抗GD2单克隆抗体 

分 类 号：R730.5[医药卫生—肿瘤]